Alpine Immune Sciences

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Pharma Voice
Thu, 11/7/24 - 11:12 am
M&A
Vertex Pharmacuticals
Alpine Immune Sciences
Eli Lilly
Morphic
Novartis
MorphoSys
Mariana Oncology
AstraZeneca
Fusion Pharmaceuticals
Lundbeck
Longboard Pharmaceuticals
AbbVie
Aliada Therapeutics
What about the company Vertex didn’t buy?
Stat
Fri, 04/12/24 - 11:05 am
Vertex Pharmaceuticals
M&A
Alpine Immune Sciences
Vera Therapeutics
IgA nephropathy
Vertex to buy kidney disease drugmaker Alpine for $4.9B
BioPharma Dive
Wed, 04/10/24 - 06:05 pm
Vertex Pharmaceuticals
M&A
Alpine Immune Sciences
IgA nephropathy
Hope springs for April inhibition
EP Vantage
Tue, 06/13/23 - 10:27 am
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Second Patient Death Shutters Alpine's Immuno-Oncology Program
BioSpace
Mon, 10/24/22 - 12:28 pm
Alpine Immune Sciences
davoceticept
patient death
clinical trials
ALPN-303
Death in Alpine's Keytruda combo trial triggers clinical hold, raises specter of earlier tragedy
Fierce Biotech
Mon, 03/7/22 - 11:01 pm
Alpine Immune Sciences
davoceticept
Merck
Keytruda
clinical trials
patient deaths
Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study
BioSpace
Wed, 06/30/21 - 09:58 pm
Merck
Alpine Immune Sciences
cancer
ALPN-202
Keytruda
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Motley Fool
Sun, 06/13/21 - 10:44 pm
Biogen
Alkermes
Alpine Immune Sciences
ASCO 2021 movers – PDS wins, but big pharma reigns
EP Vantage
Wed, 06/9/21 - 11:00 am
ASCO 2021
PDS Biotechnology
Spectrum Pharma
Black Diamond Therapeutics
Alpine Immune Sciences
Harpoon Therapeutics
Macrogenics
AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy
Endpoints
Thu, 06/18/20 - 10:55 am
AbbVie
Mitchell Gold
Dendreon
ALPN-101
immunology
Alpine Immune Sciences
lupus
Former Dendreon CEO debuts new public company in reverse merger
BioPharma Dive
Wed, 04/19/17 - 04:19 pm
Dendreon
reverse merger
Mitchell Gold
Alpine Immune Sciences
Nivalis
Former Dendreon CEO Secures $48M for Cancer Immunotherapy Startup
Forbes
Mon, 06/13/16 - 10:36 am
Mitchell Gold
Dendreon
cancer immunotherapy
Alpine Immune Sciences